Literature DB >> 15122710

Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.

Agnès Duboc1, Nöelle Hanoteau, Manuel Simonutti, Gabrielle Rudolf, Astrid Nehlig, Jose A Sahel, Serge Picaud.   

Abstract

Epileptic patients experienced an irreversible loss of their peripheral visual field upon treatment with vigabatrin (gamma-vinyl GABA), an inhibitor of the GABA degrading enzyme, GABA transaminase. Subsequently, central visual function was reported to also be irreversibly altered. This visual loss is associated with a decrease in the electroretinogram measurement localizing the deficit to the retina. To investigate its cellular origin, we treated rats daily with vigabatrin for 45 days. Two days after arresting this treatment, rats exhibited an irreversible decrease in the photopic electroretinogram, the flicker response, and the oscillatory potentials. These functional alterations were associated with a peripheral disorganization of the outer retina. However, photoreceptor damage was not limited to these disorganized areas, but cone inner and outer segments were severely injured in more central areas and their numbers were irreversibly decreased by 17 to 20%. Ultrastructural examination of the retina confirmed the presence of major photoreceptor damages, which were further supported by terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) and caspase-3 activation both indicative of photoreceptor apoptosis. This study suggests that the visual field loss in vigabatrin-treated epileptic patients may result from a sequence of events starting from cone cell injury to a more severe disorganization of the photoreceptor layer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122710     DOI: 10.1002/ana.20081

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

3.  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

Authors:  Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-30       Impact factor: 7.446

Review 4.  An overview of drug development with special emphasis on the role of visual electrophysiological testing.

Authors:  Mitchell Brigell; Cun-Jian Dong; Serge Rosolen; Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

5.  Tiagabine and vigabatrin reduce the severity of NMDA-induced excitotoxicity in chick retina.

Authors:  Francesco Pisani; Cinzia Costa; Daniela Caccamo; Emanuela Mazzon; Gaetano Gorgone; Giancarla Oteri; Paolo Calabresi; Riccardo Ientile
Journal:  Exp Brain Res       Date:  2006-01-18       Impact factor: 1.972

6.  New GABA modulators protect photoreceptor cells from light-induced degeneration in mouse models.

Authors:  Rebecca M Schur; Songqi Gao; Guanping Yu; Yu Chen; Akiko Maeda; Krzysztof Palczewski; Zheng-Rong Lu
Journal:  FASEB J       Date:  2018-01-24       Impact factor: 5.191

7.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

8.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

9.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

10.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.